E-Selectin Ligand-Engineered Neural Stem Cells for Vascular Homing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cell-based therapeutic delivery methods, such as direct injection, are inefficient and impractical for widespread conditions like multiple sclerosis due to tissue damage risks, anatomical limitations, and labor-intensive requirements, necessitating a vascular route for systemic disorders.
Innovation Solution
Intravenous administration of neural stem cells (NSCs) engineered to express Hematopoietic Cell E-/L-selectin Ligand (HCELL) coinciding with E-selectin expression on inflamed or damaged tissue to enhance cell migration and colonization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If direct injection is used to deliver cells to affected tissue, then cell delivery efficiency is improved, but tissue damage and procedural complexity increase
Solution Approach 1:
The patent uses E-selectin ligands as molecular intermediaries that mediate the interaction between administered cells and the vascular endothelium at target sites. These ligands enable cells to home to inflamed or damaged tissues through the bloodstream without requiring direct injection, thereby avoiding tissue damage while maintaining delivery efficiency.
Solution Approach 2:
The patent replaces the mechanical injection system with a biochemical homing system. Instead of using physical needles and direct mechanical delivery, the invention uses molecular recognition between E-selectin ligands on cells and E-selectin on endothelial cells to guide cells to target tissues through the circulatory system.
2Productivity
If direct injection is used for cell administration, then localized cell delivery is improved, but anatomical accessibility and operational ease deteriorate
Solution Approach 1:
E-selectin ligands serve as molecular intermediaries that enable cells to navigate the circulatory system and selectively home to target tissues based on molecular recognition, bypassing anatomical barriers and making treatment accessible regardless of tissue location.
Solution Approach 2:
The vascular homing system provides universal applicability across multiple anatomical sites and disease conditions. The same E-selectin ligand-modified cells can be administered systemically to treat various conditions including multiple sclerosis, inflammatory bowel disease, and other inflammatory or damaged tissues without requiring site-specific injection procedures.
3Ease of operation
If vascular route is used for systemic cell administration, then ease of administration is improved, but cell delivery precision to target tissue deteriorates
Solution Approach 1:
The patent imparts local quality to the cell population by equipping them with E-selectin ligands that specifically recognize E-selectin on endothelial cells at inflamed or damaged sites. This creates a localized interaction at the target tissue level while maintaining systemic circulation, achieving both ease of administration and delivery precision.
Solution Approach 2:
The patent changes the molecular parameters of the cell surface by introducing or upregulating E-selectin ligands. This parameter change enables the cells to selectively interact with E-selectin-expressing endothelium at target sites during systemic circulation, achieving precise localization without compromising ease of administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances cell delivery and colonization in inflammatory and damaged tissues, promoting tissue repair and immunomodulation, effectively treating conditions like multiple sclerosis.
Implementation Method 1
neural stem cells (NSCs) engineered to express Hematopoietic Cell E-/L-selectin Ligand (HCELL) coinciding with E-selectin expression on inflamed or damaged tissue to enhance cell migration and colonization
Data Source
Figure 1A~1D
Figure 2
Figure 3A~3C
AI summary
Methods of treatment are provided herein, including administration of a population cells modified to enforce expression of an E-selectin and/or an L-selectin ligand, the modified cell population having a cell viability of at least 70% after a treatment to enforce such expression.